Sinovac Biotech

Chinese vaccine maker selling to governments, tangled in years of ownership fights.

Sinovac's vaccine business still sells and still ships, but its board, its stock listing, and $658M of dividend money remain stuck in unresolved court fights.

Sinovac makes vaccines and sells them to governments and hospitals, especially in poorer countries. It is hard to replace because it has the right approvals from regulators and existing contracts with countries like Brazil. However, it faces two big problems: a long legal fight over who actually owns and controls the company has left the board in limbo, and the company missed filing deadlines with the stock exchange and is now under watch through May 2027. The company's home rivals, Sinopharm and CanSino, are bigger and have the same government relationships, so Sinovac's real edge is thin at home. One thing that could turn this around is if the ownership lawsuit gets solved cleanly by mid-2026, giving the company a stable leadership that can focus on keeping and growing international contracts instead of fighting in court.

• FY2025 sales $386.0M, up from $361.4M in 2024 (2025-12-31)
• $55/share special dividend, $3.96B total paid (2025-04)
• Nasdaq Panel Monitor runs through May 20, 2027 (2026-06-15)

• Board control remains an interim court order pending unresolved Antigua High Court trial. Severity: high
• Nasdaq Mandatory Panel Monitor through May 20, 2027 leaves any future filing delay able to reopen delisting risk. Severity: high
• China domestic vaccine market contraction from anti-corruption crackdown and price competition squeezing core revenue. Severity: medium
• Unresolved litigation over $658 million of withheld special dividend tied to 2018 PIPE shareholders. Severity: medium
• FY2025 swing to $59.68 million net loss despite revenue growth signals margin or one-off cost pressure. Severity: medium

Is Sinovac Biotech in financial trouble?

Sinovac is not in a cash crisis, but FY2025 results show real strain: revenue rose to $386.0 million from $361.4 million, yet the company swung to a net loss of $59.68 million (EPS -$0.83) after posting $90.9 million in net income in FY2024. There is also a $658 million special dividend still owed as of 2025-06-30, tied to ongoing lawsuits, which adds financial uncertainty on top of the operating loss.

Who are Sinovac Biotech's biggest competitors?

Domestically, Sinovac competes with Sinopharm, CanSino Biologics, and Zhifei Biological for Chinese vaccine procurement contracts as CoronaVac demand fades. CanSino is currently outperforming, swinging to profit with FY2025 revenue up 26% to about $154 million, while Zhifei projected a much larger 2025 net loss of RMB 10.7-13.7 billion. Multinationals like Pfizer, GSK, Sanofi, and MSD are pulling back from China's price-competitive vaccine market, leaving that share up for grabs among these local players.

Is Sinovac Biotech at risk from AI?

AI threat to Sinovac is rated as distant in the July 2026 data, since AI can speed up antigen discovery industry-wide but does not replace vaccine approvals or manufacturing plants. No specific AI-driven competitor was identified as an apparent threat to Sinovac's business model.

What is the biggest risk facing Sinovac Biotech right now?

The biggest risk is weak competitive protection combined with unresolved governance issues. Sinovac's revenue growth has not shielded it from state-backed or better-capitalized rivals, and it lacks pricing power or exclusive access that would provide that protection. On top of that, the Antigua court dispute over the 2025 shareholder meeting and board control, and the Nasdaq Mandatory Panel Monitor period, both run until around 2027-05, leaving shareholder footing unresolved in the meantime.

Is Sinovac Biotech's vaccine business still growing?

Yes, on a revenue basis: FY2025 sales reached $386.0 million, up from $361.4 million in FY2024, and H1 2025 sales of $130.3 million slightly exceeded the $128.7 million from H1 2024. However, growth in revenue did not translate to profit, as the company posted a $59.68 million net loss for FY2025 versus a $90.9 million profit a year earlier.

What should I watch to see if Sinovac Biotech's situation improves?

Two dated events matter most: the Antigua High Court's expected final ruling on the disputed 2025 shareholder meeting and board control fight, due by 2027-05, and whether Sinovac avoids a renewed Nasdaq delisting notice before its Mandatory Panel Monitor period ends, also by 2027-05. Until then, Sinovac remains classified as protection under test in the July 2026 assessment, with revenue growth continuing but unresolved shareholder and listing risks weighing on the outlook.

• 2026-06-15Sinovac announces regained Nasdaq Global Market compliance
• 2026-05-29Sinovac receives Nasdaq deficiency notice for late 2025 annual report
• 2026-05-20Sinovac regains Nasdaq compliance after late-filing notice
• 2026-05-18Delaware Chancery shareholder class action against Sinovac and Vivo Capital dismissed
• 2026-05FY2025 sales $386.0M and net loss $59.68M disclosed in 20-F
• 2025-12-17Antigua High Court issues interim order giving board control to Yan-led slate
• 2025-06-20SDNY denies Prime Success v. Sinovac case tied to 2018 PIPE investment
• 2025-04Sinovac declares $55.00 per share special dividend, about $3.96B total
• 2024-12Sinovac acquires Sinovac Chengdu Biological Products Co Ltd
• 2024-01CoronaVac production discontinued

• Sinovac Biotech
• Barron's company data (2025-07-09)
• Prime Success v. Sinovac SDNY opinion
• Antigua Court Interim Order (2025-12-17)
• Simpson Thacher dismissal notice (2026-05-19)
• Sinovac 2025 financial results (2026-06-07)
• Nasdaq deficiency notice (2026-05-29)
• Nasdaq compliance announcement (2026-06-15)
• Sinovac 2025 earnings (2026-06-05)
• Sinovac H1 2025 results (2026-07-14)
• Chinese vaccine makers overseas contracts
• GlobalData company profile